Nkarta Therapeutics

Focus: Nkarta Therapeutics is a South San Francisco-based biotechnology company founded in 2017 focused on allogeneic cellular immunotherapy, specifically CAR NK cell therapies for oncology and immunology indications. The company operates as a pre-revenue biotech with a focused pipeline in early-stage development.

Immunology Oncology Cell Therapy

Profile data last refreshed 17h ago · AI intelligence enriched 2w ago

Open Jobs

Should You Work at Nkarta Therapeutics?

AI assessment

Nkarta offers early-stage scientific opportunity in a novel modality but presents significant execution risk and career mobility constraints typical of underfunded early-stage biotech.

Why Work Here

Pioneer in allogeneic CAR NK cell therapy platform—an emerging modality with fewer competitors than CAR-T, offering early-stage career visibility in a novel space

Data completeness

4/9 — Basic

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

NKX101 - CAR NK cell therapy

Relapsed/Refractory AML

PHASE_1

Clinical Trials (1)

NCT04623944NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

Phase 1

Help build intelligence for Nkarta Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Therapeutic focus spans high-unmet-need indications (relapsed/refractory AML, lupus nephritis, systemic sclerosis), attracting mission-driven talent in immunotherapy and rare disease

Located in South San Francisco biotech hub with access to world-class research networks and talent ecosystem

Watch Out For

Only 1 active job opening signals minimal hiring and likely constrained growth capacity; career advancement opportunities may be limited
All programs in Phase 1–Phase 1/2 with no Phase 3 data means 7–10+ years to potential regulatory approval—lengthy pre-revenue runway increases dilution and cash-burn risk
No disclosed funding, financials, employee count, or recent news raises visibility concerns; limited transparency on company stability or resource allocation

Generated by Claude from Nkarta Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

NKX019

Lymphoma, Non-Hodgkin

PHASE_1

Clinical Trials (1)

NCT05020678NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Phase 1

NKX019

Systemic Sclerosis

PHASE_1_2

Clinical Trials (1)

NCT06733935A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)

Phase 1/2